Obesity News

BOSTON — From 2019 to 2023, insurance covered GLP-1 receptor agonist prescriptions at a Texas hospital for less than 70% of young people with type 2 diabetes and less than 40% of those with obesity.

Adults with class II to III obesity may have an increased risk for poor cardiac outcomes but not kidney risk after adjusting for potential confounders, according to multicenter data.

Patients with obesity are at increased risk for CVD, in part due to the promotion of an atherogenic lipid profile, according to a speaker.

Endocrinology providers and researchers will gather in Boston beginning Saturday as the Endocrine Society holds its 2024 annual meeting.

Insufficient sleep was tied to poorer cognition and attention in adolescents who were classified as having overweight or obesity based on their BMI compared with those with normal weight, according to a recent study in JAMA Neurology.

The National Lipid Association Scientific Sessions will be held Thursday to Sunday and will spotlight emerging areas of research such as “cardio-rheumatology,” a renewed push to reinstate LDL as a health system quality metric and more.

A new study in the Journal of Osteopathic Medicine showed that higher BMIs before pregnancy correlated with increasing risks for maternal and neonatal morbidity.

Adults with type 1 diabetes and overweight or obesity prescribed tirzepatide off-label had a reduction in body weight and improvements in HbA1c and continuous glucose monitoring metrics, according to data from a real-world study.

Women with polycystic ovary syndrome, obesity and irregular menses were more than twice as likely to experience spontaneous ovulation during the year after undergoing bariatric surgery compared with medical therapy, researchers reported.

Dispensing of GLP-1 receptor agonists increased nearly 600% among adolescents and young adults in the United States from 2020 to 2023 and was particularly significant among girls and young women, a new study showed.